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Activation of the terminal complement cascade in renal infarction.
Ischemic injury is an important cause of functional derangement in the
kidney. The complement (C) system has previously been shown to be an
important mediator of ischemic tissue injury in myocardial infarction. In
the present study we therefore investigated the possible role of C in renal
ischemic lesions. The deposition and distribution of various C components
(Clq, C3c, C3d, C4, C5, C6, C9) and regulators [vitronectin, clusterin and
protectin (CD59)I in human renal infarction lesions were studied by
indirect immunofluorescence microscopy. Deposition of components of
the terminal C complex (TCC), as well as vitronectin and clusterin, were
observed throughout the infarcted areas. The strongest deposits were seen
on the membranes of tubular epithelial cells and in the tubular lumina of
the infarction areas, especially in the border zone between normal and
infarcted tissue. Using markers for different segments of tubuli (Tamm-
Horsfall glycoprotein and brush border antigens) it was possible to localize
deposits of TCC predominantly to the proximal tubuli. In the glomeruli of
the infarcted areas deposits of TCC were seen as a crescent-like pattern at
and immediately beneath the Bowman's capsule. The expression of cell
membrane-associated protectin was diminished in tubular epithelial cells
of the infarction lesions. A clue for the possible mechanism of C activation
in renal infarction was obtained from in vitro experiments, in which the
contact of normal human serum with urine was observed to lead to the
generation of TCC. Thus, in renal ischemic lesions C may become
activated when C components enter the intratubular urinary space of
ischemic tubuli. Our results suggest that local C activation in association
with ischemic renal injury leads to the generation of terminal C complexes
and an inflammatory response whereby a healing process can begin.
The complement (C) system is an important group of plasma
proteins, the main physiological function of which is to participate
in the mediation of inflammation and elimination of foreign cells
[1]. The principal products of C are the chemotactic and vasoac-
tive anaphylatoxins, C3a and C5a, the C3b opsonin and the
cytolytic membrane attack complex (MAC). Cells in direct contact
with plasma are protected against the cytolytic and destructive
potential of C by soluble factors, such as C4b binding protein [2],
factor H [3], vitronectin [I, clusterin [5, 6], and by cell membrane
regulators, like complement receptor type 1 [71, membrane cofac-
tor protein [81, decay accelerating factor [9] and protectin (CD59)
[10—131.
Progress has recently been made in the understanding of
changes in the microcirculation of renal ischemic lesions, yet the
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precise molecular mechanisms leading to renal ischemic tissue
injury are not well understood [14, 15]. In general, inflammatory
responses usually occur in ischemic tissues during their reperfu-
sion [14—181. Complement activation has been suggested to play a
central role in the reperfusion injury, such as after myocardial
ischemia [18, 19]. The effects of C in ischemic areas are initially
mediated by C3a and C5a, which may cause changes in vascular
permeability, vasoconstriction, chemotaxis and occlusion of, for
example, coronary microcirculation by accumulation of polymor-
phonuclear leukocytes [18, 20, 21]. Although probably basically
aimed at clearance and at launching a reparative healing process
[22], the formation of MAC in the ischemic tissue may further
augment cell damage by its direct cytolytic effect and by its ability
to enhance other inflammatory effector mechanisms and proco-
agulant responses of platelets [19, 23, 24]. Recent experimental
and clinical studies have shown that C is activated in myocardial
infarction lesions, and that C activation, conceivably triggered by
ischemic changes of the myocardium, may enhance cell injury
during acute myocardial infarction [22, 25—29]. These results
prompted us to study the possible role of C in ischemic lesions of
the kidney.
In the present study we investigated the distribution, that is,
deposition or expression, of C components and regulators in renal
infarction lesions by indirect immunofluorescence microscopy. In
analogy with previous studies of human and experimental myo-
cardial infarction [22, 25—29] we demonstrate that the terminal C
pathway becomes activated in human renal infarction. The termi-
nal C complex (TCC) and its regulators, vitronectin and clusterin,
were codeposited in the ischemic lesions of human kidney,
whereas the expression of protectin was diminished. These results
suggest that C activation is widely associated with ischemic




Human kidney specimens were obtained from autopsies of 10
patients within one to three days post mortem. Five of the patients
had renal infarction, which was diagnosed by gross and his-
topathological findings. The causes of renal infarctions were
embolization (N = 1) and thrombosis (N = 4). The ages of the
infarctions were histologically estimated to vary between one and
seven days. None of the patients had died because of kidney-
related causes. The causes of death of the patients with renal
infarction were pneumonia (N = 1), lung cancer (N = 1),
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Fig. 1. Immunofluorescence demonstration of complement components in a renal infarction area (A-G) and in a normal kidney (H, I). In the infarcted
renal tissue Clq (A), C3d (B) and C4 (C) are localized mainly along the basement membranes, whereas deposits of C5 (B), C6 (E) and C9 (F) were
observed on the renal epithelial cells and in the lumen of tubuli. No deposits of C5 and C6 are seen in the glomeruli, but C9 is occasionally seen in the
peripheral subcapsular area of some glomeruli. Deposits of IgG are not evident in the infarction lesions (G). In normal areas of human kidney only the
basement membranes of the tubuli appear positive for C5 (H) and C9 (I). Paraffin sections (x350).
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pulmonary embolism (N = 1), cerebral (N = 1) and myocardial
infarction (N = 1). No other renal diseases than renal infarction
were detected in the affected kidneys. Control samples (N = 5)
were obtained from the kidneys of patients who had died of
non-kidney-related causes. The control renal specimens appeared
morphologically normal. The tissue samples were embedded in
paraffin, sectioned, deparaffinated and stained with hematoxylin-
eosin according to standard histological methods.
Immunohistological methods
For immunohistological staining procedures the deparaffinated
tissue sections were treated with pepsin (1% wt/vol, pH 1.8) at
37°C for 30 minutes, and finally washed with phosphate-buffered
saline (PBS), pH 7.4, as described earlier [29]. The sections were
incubated with the different antibodies for 30 minutes at +22°C.
The following primary antibodies were used: rabbit polyclonal
antisera against Clq, C3c, C3d, C4, vitronectin, a2-macroglobulin,
transferrin, fibrin (Behringwerke AG, Marburg, Germany), CD59
[11], a-chain of clusterin [30]; goat polyclonal antibodies against C
components CS, C6 and C9; rat anti-CD59 (YTH53.1) [11] and
anti-glycophorin A (YTH89.1) [11]; and mouse anti-CD59 (BRIC
229; Bio-Products Laboratory, Elstree, UK) monoclonal antibod-
ies (mAb). After rinsing with PBS, the sections were incubated
with fluorescein isothiocyanate- (FITC-) conjugated antibodies
against rabbit, goat, rat and mouse immunoglobulins (Dakopatts,
Glostrup, Denmark), respectively.
To determine the segments of renal tubuli, to which the C
components were deposited, markers for proximal (antiserum
against brush border antigen [31]) and distal (antiserum against
Tamm-Horsfall glycoprotein [32]) tubuli were used. Binding of
these rabbit antibodies was detected by FITC-conjugated antibod-
ies against rabbit immunoglobins (Dakopatts).
In control experiments three different procedures were used:
(1.) the primary antibody was omitted; (2.) nonimmune rabbit and
goat sera, or (3.) rat or rabbit antibodies of known specifities other
than C components (anti-transferrin, anti-glycophorin A, anti-a2-
macroglobulin, anti-IgG, anti-IgM and anti-fibrin). Except for
anti-fibrin antibodies no positive reactions with these control
antibodies were seen (Results).
The immunostained sections were mounted in Mowiol [33] and
studied in a Zeiss Standard light microscope equipped with a filter
specific for FITC fluorescence. Sections stained with hematoxylin-
eosin were examined using a Leitz Dialux 22 microscope.
Phospholipase C treatment
Frozen sections of normal human kidney were incubated with
Bacillus cereus phosphatidylinositot-specific phospholipase C (1
lU/mi; Sigma, St. Louis, MO, USA) in PBS or with PBS alone for
30 minutes at +37°C. After washing with PBS the sections were
stained for CD59 with the BRIC 229 mAb.
In vitro activation of complement
The ability of human urine to activate the C system was studied
in in vitro experiments. Human urine (pH 6.5) and neutralized
human urine (pH 7.4) (1:2, 1:4, 1:8, 1:16 or 1:32 dilution into PBS)
were incubated with normal human serum (1:2 dilution) for 30
minutes at 37°C. Thereafter the concentration of soluble C5b-9
(SC5b-9) complexes in the samples was measured by a modified
enzyme immunoassay method (EIA; Quidel Corp., La Jolla, CA,
USA). The diluted samples were incubated for 60 minutes in wells
coated with a mAb against SC5b-9 neoantigens. After washing (5
X 5 mm) with 0,05% Tween 20/PBS, horseradish peroxidase-
labeled goat polyclonal antibodies to C6 and C7 were applied to
the wells and incubated for 60 minutes. After washing (5 X5 mm)
with 0.05% Tween 20/PBS, the chromogen (2-2'-Azino-di-(3-
ethylbenzthialzoline sulfonic acid) diammonium salt, 0.7%) was
incubated in wells for 30 minutes and, finally, absorbance at 405
nm was measured. The concentration of SC5b-9 complexes was
determined with the help of the SC5b-9 standards of the ETA kit.
As controls, normal human serum and human urine (1:2 dilution
in PBS) held on ice or incubated for 30 minutes at 37°C were used.
Results
Gross and histopathologic findings
In gross examination of the kidneys, the infarcted areas were
seen as wedge-shaped lesions extending from the cortex to the
medulla. They varied from red to light yellow in color and were
demarcated by a purple hemorrhagic zone from the surrounding
normal tissue. Microscopically, the samples showed acute coagu-
lation necrosis of the tubules and necrosis with occasional hem-
orrhage within the glomeruli.
The ages of the infarctions were estimated to vary between one
and seven days as judged by either the lack or the formation of
granulation tissue at the site of the infarction lesions. Proliferating
capillaries and an increase in fibrous tissue were seen at the older
infarction sites. An active inflammatory reaction with infiltrating
polymorphonuclear leukocytes was observed at the edges of
several infarction lesions. The small branches of renal arteries
supplying the infarcted areas were occasionally seen to be com-
pletely occluded by mural thrombi.
Complement deposits in normal and infarcted human kidney
The basement membranes of blood vessels, tubuli and collect-
ing ducts of normal human kidneys often showed a continuous
linear fluorescence when stained for C components (Clq, C3c,
C3d, C4, CS, C6, C9) (Fig. 1). In normal glomeruli, the Bowman's
capsules were stained faintly for C3d, CS, C6 and C9.
Deposits of TCC (CS, C6, C9) were observed throughout the
wedge-shaped infarction areas of the human kidneys. The stron-
gest deposits of TCC were detected in areas surrounding the
necrotic centers of the infarction (Fig. 1). The intensity of the
TCC-associated fluorescence, as well as the extent of the deposits
appeared to gradually diminish towards the necrotic center of the
lesion, whereas the demarcation zone between the normal and the
infarcted tissue appeared distinct (Fig. 2C). The deposits of TCC
could be detected in the infarcted tubuli, whereas only C9 was
detected within the ischemic glomeruli (Fig. 1 D-F). No difference
in the distribution of C deposits in the tubular structures between
medullary and cortical areas could be observed.
To define more precisely the localization of TCC, markers for
different segments of tubuli were used. Rabbit antiserum against
brush border antigen [31], which reacts with proximal tubuli, and
rabbit antiserum against Tamm-Horsfall glycoprotein, which re-
acts with the distal tubuli [32], were used to stain the samples. The
deposits of TCC were more often localized to the proximal than to
distal tubuli (Fig. 3). In both distal and proximal tubuli the
deposits of TCC appeared at and around the epithelial cells as a
relatively diffuse fluorescence surrounding the entire epithelial
cell layer (Figs. 1 to 3). Often a positive staining reaction was also
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Fig. 2. Immunofluorescence detection of soluble regulators of TCC and C9 in renal infarction. Deposits of vitronectin (A, D), clusterin (B, E, F) and C9(C, G) are present in an infarcted zone. The border between normal (top) and infarcted (bottom) renal tissue is indicated by arrows (A-C). In normal
kidney specimens basement membranes and connective tissue matrices often stained positive for vitronectin (H) and clusterin (I). Paraffin sections.
(A-C, X70; D-I, X350).
seen within the tubular lumen. Epithelial cell borders were reactions indicated that the deposits consisted mainly of the
occasionally distinctly delineated, suggesting that the TCC depos- terminal components of C (C5, C6, C9) (Fig. 1 D-F). The staining
its could be localized directly on the cell membranes. The staining for CS and C6 was mainly localized to the tubular lumina, whereas
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Fig. 3. Immunofluorescence localization of C9 and clusterin in different segments of ischemic tubuli in the renal medulla. Sequential paraffin sections of a
single infarcted kidney specimen were immunostained for C9 (A, E), clusterin (B, F), brush border antigen (a marker of proximal tubuli; C, G) or
Tamm-Horsfall glycoprotein (a marker for distal tubuli, D, H). C9 and clusterin deposits were preferentially localized in proximal tubuli. Distal tubuli
are marked by open arrows and proximal tubuli by closed arrows (E-H). (A-D, X200; E-H, X450).
deposits of C9 were seen both on the tubular epithelial cells as
well as within tubular lumina (Fig. 1 D.F). In the glomeruli of
some lesions a strong immunoreaction for C9 was detected along
the Bowman's capsules and in the subcapsular space beneath it
(Fig. iF). Thus the pattern of TCC deposition in the infarction
lesions clearly differed from that seen in the histologically normal
kidneys. Deposits of the early C components (Clq, C3c, C3d, C4)
were seen along the basement membranes of tubular and glomer-
ular epithelial cells both in the infarction lesions and in the normal
kidney. In the infarcted samples no deposits of Clq, C3c, C3d or
C4 could be seen on the tubular epithelial cells (Fig. 1).
In control experiments the antibodies against human IgG (Fig.
1), 1gM, ci2-macroglobulin and transferrin did not stain the
tubular basement membranes of normal or infarcted kidneys in
the same way as anti-C antibodies did (Figs. 1 and 2 C, G).
Deposits of fibrin were observed as patch-like lesions both in the
tubuli and the glomeruli of the lesions, suggesting that the
coagulation cascade had become activated in the infarction le-
sions and that reperfusion of blood had occurred. The staining
pattern of fibrin was partly reminiscent of that obtained with
anti-C5, C6 and C9 antibodies. However, fibrin was more often
and more diffusely localized to the glomeruli than deposits of
TCC.
Regulators of C in normal and infarcted kidneys
The localization of C regulators, vitronectin, clusterin and
protectin (CD59), was studied in the same infarcted and control
kidney specimens as the various C components described above.
In normal kidneys or in the non-infarcted areas of the affected
kidneys, vitronectin and clusterin were mainly seen along the
basement membranes of blood vessels, tubuli and collecting ducts,
and sometimes in the surrounding connective tissue matrix (Fig.
2). This pattern was similar to that seen with antibodies against C
components (Clq, C3d, C4, C5, C6, C9). Protectin, on the other
hand, was expressed on the cell membranes of normal tubular and
collecting duct epithelial cells. Also, the capillary loops and the
Bowman's capsules of the glomeruli showed a positive reaction
when stained with the anti-protectin mAb (Fig. 4A). To test for
Fig. 4. Erpn'sskn; of protectin in normal human kidney and its sensttiii V to gkeophosphomosito!-sptcd:r phusphohpase C (I IV:,ii!. 30 mitt a? +37C).
Frozen sections of normal human kidney samples 'cere treated with PI3S t or phospholipase C (B) and immunostained for protectin with the BRIC
22L) anti-protectin mAli (X350).
Fig. 5. Comparison between (9 deposition (A) and expression ofprotectin (by Yfl/53. I) II) in a renal infarction lesion. C') deposits were observed iii the
inturctecl areas (left) (A) sliereas the expression of protectin was dimini,hed (B). Sequential paraffin sections (x2(X)).
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rozen sections of normal human kidney samples were treated with PBS (A) or phospholipase C (B) and im unostained for protectin with the BRIC
9 anti-protectin Ab
i . . parLon between C9 deposition (A) and expression of protectin (by YTH .1) (B  i  a renal infarction lesion. C9 deposits were observed in the
i far t d reas (left) ( ) wherea  t  r sion of r t cti  s di i is  ( ). ti l r ffi  ti  (X200).
the type of cell membrane anchorage of renal protectin, frozen
sections of normal human kidney were treated with phosphatidyl-
inositol-specific phospholipase C. After the enzyme treatment
total loss of protectin expression was seen in the various epithelial
and endothelial cell membranes of tubuli, glomeruli and blood
vessels (Fig. 4B). This indicates a glycosyiphosphatidylinositol-
type anchorage for protectin in the kidney epithelial cells. As a
control for the anti-protectin (YTH53.1) mAb we used anti-
glycophorin A mAb (YTH89.1), which is of the same isotype as
YTH53.1 (rat IgG2). YTH89.1 stained only red blood cells in the
blood vessels and extravasated erythrocytes within the parenchy-
mal tissues. No staining was seen in the renal parenchymal tissue
itself.
In the infarcted kidneys vitronectin and clusterin were mainly
seen as deposits around the tubular epithelial cells of the infarc-
tion lesions colocalizing with the deposits of TCC (CS, C6, C9)
(Figs. 2 and 3). No deposits of these regulators could be observed
in the glomeruli or in the intracapsular space. Clusterin was seen
as a granular fluorescence pattern in and around the tubular
epithelial cells (Fig. 3 B, F). This fluorescence pattern was
somewhat different from the more diffuse or patch-like pattern
observed with the TCC deposits (Figs. 2 C, G and 3 A, C).
The expression of protectin was diminished in the renal infarc-
tion lesions (Fig. 5). The diminished expression of protectin
localized to areas with deposits of TCC (Fig. 5).
Activation of the complement terminal pathway by urine in vitro
The ability of normal human urine to activate the C system of
normal human serum (NHS) was examined in in vitro experiments
(Fig. 6). Activation of the terminal pathway was examined by
quantitating soluble SC5b-9 complexes by an enzyme immunoas-
say. When various dilutions of normal urine (pH 6.5) were
incubated with NHS, significant activation of the terminal path-
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Dilutions of urine
Fig. 6. Generation of TCC in normal human semm by human urine.
Normal human serum was incubated with various dilutions of urine (pH
6.5 or 7.4) for 30 mm at 37°C. As controls, normal human serum or urine
were incubated with PBS for 30 mm at 37°C or kept on ice. SC5b-9
complexes were quantitated by an ETA method. Mean + SD values (N =
6) are shown. Symbols are: (•) urine, pH 6.5; (L) urine, pH 7.4; ()
controls.
complexes in NHS increased up to 13 times the basal level.
Somewhat lower, but still significant activation was seen after
adjustment of the urinary pH to neutral (pH 7.4). Control
incubation of NHS with buffer alone led to the formation of only
negligible amounts of SC5b-9 complexes. The level of SC5b-9 in
normal human urine was below the detection limit of the assay.
Discussion
In the present study we have shown that the terminal cascade of
the C system becomes activated in acute ischemic lesions of
human kidney. Terminal components of C were codeposited with
the soluble regulators vitronectin and clusterin throughout the
wedge-shaped infarction areas. C activation occurred both in the
glomeruli and tubuli, as well as in the blood vessel walls, although
it was most notable in the proximal renal tubuli.
In the normal kidney, deposits of C, vitronectin and clusterin
were detected mainly along the basement membranes of both
tubular and glomerular epithelial cells. This is in line with several
previous studies [34—361. C deposits on the basement membranes
may represent the end result of normal C turnover. In the
infarcted areas the predominant localization of TCC in tubuli
might be explained by the diffusion of C components from
intertubular capillaries through the injured tubular epithelial cell
layer or from injured glomeruli via primary urine to the tubular
lumen and tubular epithelial cells. As no deposits of other serum
proteins, such as IgG, 1gM, a2-macroglobulin or transferrin were
observed in the infarcted areas, the deposition of TCC and its
regulators in the ischemic tubular lesions conceivably does not
solely reflect passive accumulation of serum proteins into the
infarcted area, but may be a more specific phenomenon.
The lack of early C components (Clq, C3, C4) from the injured
tubular epithelial cells and from the tubular lumen suggests that
the activation of C may take place initially in the fluid phase,
whereafter the terminal C components become deposited on the
tubular epithelial structures. The soluble components of C may
then be washed out from the tubular lumen, whereas the MAC
may become inserted into the ischemic tubular cell membranes.
C5 and C6 were mainly seen in the tubular lumen, whereas C9
deposits were also seen on the epithelial cell membranes of
ischemic tubuli, which suggests that at least a proportion of the
TCC was in the form of MAC. In contrast, in various forms of
glomerulonephritis the MAC complexes have predominantly been
detected in glomeruli [34—36], as opposed to the tubular localiza-
tion of TCC in the infarcted kidney. Furthermore, in glomerulo-
nephritis also components of the early C cascade (Clq, C3, C4)
have usually been seen in the glomerular lesions [34—36]. Thus,
the C system is probably activated by different triggering mecha-
nisms in the glomerulonephritides than in the renal infarction.
The hypothesis of an initial fluid phase activation of C in renal
infarction is further supported by our in vitro experiments showing
that contact of human serum with urine results in the formation of
soluble SC5b-9 complexes. According to this hypothesis C activa-
tion could thus take place in the proximal tubular urine when C
proteins enter the urinary space in the injured areas. The obstruc-
tion of blood flow may then lead to the cessation of glomerular
filtration and urine production. Furthermore, under these condi-
tions the primary urine may become stagnated and could favor C
activation. One possible triggering mechanism of C activation in
renal infarction in vivo could be the generation of ammonia in the
lumina of the renal tubuli that have become obstructed by swollen
epithelial cells during progressive ischemic tubular injury [14, 15].
This hypothesis is in accordance with earlier studies indicating
that ammonia is able to trigger spontaneous activation of the
alternative C pathway by interacting with the thioester of C3 [37,
38]. Activation of C might also be induced by acidosis in the
ischemic lesions, as suggested by our in vitro experiments (Fig. 6),
or by proteolytic enzymes originating from blood (plasmin) or
lysosomes of injured cells. Another possible C activating factor in
kidneys is the brush border of proximal tubuli, which in in vitro
experiments has been demonstrated to activate the alternative C
pathway [39]. Further possible activating mechanisms include the
formation of oxygen radicals, which can lead to the activation of
C5 by converting CS to a C5b-like metabolite, which then reacts
with C6 and initiates TCC formation [40, 41].
Proximal tubuli are known to be more susceptible to ischemic
injury than other segments of the nephron [14, 15, 42]. During the
infarction process the proximal tubular cells are injured earlier
than the distal tubular cells and may therefore become a preferred
focus of C attack. Interestingly, in this study we observed that the
TCC deposits were mainly localized to the proximal tubuli in the
ischemic lesions. This may imply that C activation enhances the
ischemic damage of renal proximal tubuli and/or that proximal
tubular cells are relatively strong activators of C or even that they
may contain specific receptors for the terminal complement
complexes. The susceptibility of proximal tubuli to C attack could,
in part, be due to a low level of expression of MAC inhibitors in
the epithelial cells of proximal tubuli. In accordance, the main cell
membrane inhibitor of MAC, protectin, has been reported to be
sparsely expressed in the proximal tubuli of both human and rat
kidneys [43, 44]. On the other hand, in this study we observed that
the expression of protectin was diminished on the tubular epithe-
hal cell membranes throughout the infarction lesions. This is in
accordance with our previous study showing that protectin is lost
in ischemic myocardial lesions from areas where MAC has
become deposited [29]. The mechanism of loss of protectin
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expression in ischemic areas is still unknown, but vesicular de-
tachment of the GPI-anchored protectin from cell membranes or
cleavage of the GPI-anchor by specific phospholipases could be
involved. As demonstrated in our previous study [29] and in
Figure 4, both heart and kidney protectin are sensitive to phos-
pholipase C. Moreover, tubular epithelial cells of human kidney
seem to be better protected against the early than the late cascade
of C. This may be due to the fact that two important cell
membrane inhibitors of the early C pathway—membrane cofactor
protein (MCP) [45] and decay accelerating factor (DAF) [46]—
are expressed by these cells. Thus, the distribution of membrane
regulators of C in the kidney might partly explain why no deposits
of the early C components are present in the ischemic renal tubuli.
It has been suggested that a primary physiological function of
complement activation in association with the deposition of
vitronectin and clusterin in the ischemic areas could be the
recruitment of subsequent clearance mechanisms that begin the
healing process in the infarcted and pen-infarction areas [22, 47,
48]. An important function of vitronectin and clusterin is to keep
terminal C complexes soluble, and thereby to inhibit the forma-
tion of MAC [4, 6]. However, the association of vitronectin and
clusterin with the TCC may lead to other consequences than
inhibition of C lysis, since these molecules seem to associate also
with a cytolytically active MAC [22, 35, 36, 48—50]. It has been
suggested that an increased expression of clusterin in the infarcted
areas might enhance apoptosis of injured cells [47], but the exact
relationship between increased clusterin expression and apoptosis
remains to be determined. It has also been suggested that
clusterin and vitronectin could mark irreversibly injured cells for
clearance by apoliproteins and phagocytes [22, 47,48,51, 52]. This
line of reasoning is supported by our finding that the fluorescence
pattern of clusterin in ischemic tubular epithelial cells was gran-
ular. This result may indicate that the amphiphilic clusterin
molecule is associated with microparticles that could be end
products of the membrane disruption caused by the infarction
process. Clusterin could thus help in the clearance of lipid-rich
cell debris [47, 48, 51, 52].
The primary cause of ischemic injury of the kidney and other
organs is the cessation of blood flow. However, it has been shown
that the so-called reperfusion injury in the infarction lesions
causes additional injury to these areas and that C activation may
be one of its effector mechanisms [18, 19]. Interestingly, a recent
study based on an animal model of renal ischemic injury has
shown that the reperfusion injury of the kidney could be inhibited
by treatment of the experimental animal with anti-ICAM-1 mono-
clonal antibodies [17]. Similarly, treatment with recombinant
soluble complement receptor type 1 (5CR1) has been shown to
reduce the size of experimental myocardial infarction [28, 53],
ischemic injury of limb muscle [54] and small intestine [55].
Considering the possible role of complement activation in the
pathogenesis of myocardial infarction, our findings of C deposits
in infarcted kidneys should motivate similar intervention studies
in the experimental ischemic injury of kidney.
In conclusion, we have here, for the first time, demonstrated
that activation of the C system is associated with renal ischemic
injury. Interestingly, our results suggest that spontaneous activa-
tion of the terminal C pathway, starting from the level of C5,
might also occur in vivo in renal infarction lesions, and not only in
in vitro models. The combined results of this and previous studies
suggest that C activation and TCC formation widely accompany
ischemic injuries of human organs.
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